What is United Therapeutics's D&A?

United Therapeutics (UTHR) reported D&A of $22.6M in Q1 2026.

How has United Therapeutics's D&A changed year-over-year?

United Therapeutics's D&A increased by 14.1% year-over-year, from $19.8M to $22.6M.

What is the long-term trend for United Therapeutics's D&A?

Over 4 years (2021 to 2025), United Therapeutics's D&A has grown at a 14.4% compound annual growth rate (CAGR), from $49.9M to $85.6M.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

United Therapeutics UTHR D&A

D&A at other companies

Tenet HealthcareTHC

$229M+11.2%

Johnson & JohnsonJNJ

$1.96B+0.8%

InsmedINSM

$2.93M+55.8%

Ethos Technologies, Inc. LIFE

$162K-3.0%

LQD

Liquidia CorporationLQDA

$497K+10.2%

AmgenAMGN

$1.12B-19.5%

Other financials

Income statement

See full

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Balance sheet

See full

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Cash flow

See full

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Valuation

See full

Market cap$26.25B+90.4%

P/E20.4×+9.3×

P/S8.3×+3.8×

Profitability

See full

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Returns & leverage

See full

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is United Therapeutics's D&A?: United Therapeutics (UTHR) reported D&A of $22.6M in Q1 2026.
How has United Therapeutics's D&A changed year-over-year?: United Therapeutics's D&A increased by 14.1% year-over-year, from $19.8M to $22.6M.
What is the long-term trend for United Therapeutics's D&A?: Over 4 years (2021 to 2025), United Therapeutics's D&A has grown at a 14.4% compound annual growth rate (CAGR), from $49.9M to $85.6M.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.